Special populations stand at the head of the US FDA’s long list of post-marketing priorities for Gilead Sciences, Inc.’s antiviral Veklury (remdesivir), which became the first product approved to treat COVID-19 on 22 October 2020.
Veklury was approved just two and a half months after NDA submission, making it one of fastest novel approvals in agency history; Gilead’s IND for Veklury in COVID-19 only dates back to February 2020. One of the tradeoffs of that speed can be seen in the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?